[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neuroblastoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":307,"states":319},"Neuroblastoma",70,58,[8,16,22,29,35,41,48,55,61,67,73,79,85,91,97,102,108,114,119,125,131,138,144,150,156,161,167,173,179,185,191,197,202,208,214,220,226,232,238,244,250,255,261,266,272,278,284,290,296,301],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06057948","A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma",[12],"Phase 2","RECRUITING","2026-08-26T02:18:42.501841Z","2026-07-30T01:46:14.460692Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05489887","Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma",[12],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.806484Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06995872","Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan\u002FTemozolomide for Children and Young Adults With Relapsed\u002FRefractory Neuroblastoma",[26],"Phase 1","2026-08-26T02:18:46.137046Z","2026-07-05T05:32:16.726450Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04837547","PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy",[26],"2026-08-26T02:19:06.150683Z","2026-07-05T03:45:20.247004Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT02559778","Pediatric Precision Laboratory Advanced Neuroblastoma Therapy",[12],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:29.219995Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06803875","Study of hALK.CAR T Cells for Patients With Relapsed\u002FRefractory High-risk Neuroblastoma",[45],"Phase 1\u002FPhase 2","2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.139155Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT03126916","Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)",[52],"Phase 3","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:28.673665Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT03721068","Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed\u002FRefractory Neuroblastoma or Relapsed\u002FRefractory Osteosarcoma",[26],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:28.120445Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06172296","Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma",[52],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:27.977971Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07211737","NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma",[26],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.839814Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06528496","N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.797534Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07027748","Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma",[26],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.757819Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05400603","Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed \u002FRefractory Neuroblastoma or Refractory\u002F Relapsed Osteosarcoma",[26],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.744003Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07085338","A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma",[12],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:27.490708Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":46,"content_modified":101},"NCT06450041","NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial",[12],"2026-05-05T02:43:27.307428Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT03294954","GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma",[26],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:26.965898Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT02112617","Phase II Study of Proton Radiation Therapy for Neuroblastoma",[],"2026-08-03T03:50:55.473026Z","2026-05-05T02:43:26.950941Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":33,"content_modified":118},"NCT04936529","A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma",[12],"2026-05-05T02:43:26.905340Z",{"nct_id":120,"title":121,"phases":122,"status":13,"updated_at":123,"content_modified":124},"NCT02605421","Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma",[12],"2026-08-26T02:19:01.741747Z","2026-05-05T02:43:26.771448Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT06540963","Tipifarnib and Naxitamab for Relapsed\u002FRefractory Neuroblastoma",[12],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:26.769225Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":136,"content_modified":137},"NCT07549321","A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients",[135],"Phase 2\u002FPhase 3","2026-08-26T02:17:23.750999Z","2026-05-05T02:35:31.718573Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT04211675","NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab",[45],"2026-08-26T02:18:05.435729Z","2026-04-29T02:57:57.145713Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT07172958","Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed\u002FRefractory Embryonal Tumors (SABRE)",[26],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:29.230684Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06721689","PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors",[45],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.347885Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":65,"content_modified":160},"NCT00107289","Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma",[12],"2026-05-05T02:43:27.512726Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT05521984","Targeting Pediatric Brain Tumors and Relapsed\u002FRefractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)",[26],"2026-08-26T02:15:15.642947Z","2026-07-05T05:32:16.804377Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[45],"2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT06541262","Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors",[45],"2026-08-26T02:16:21.385056Z","2026-07-05T03:45:20.453347Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT06465199","Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",[45],"2026-08-26T02:15:58.452248Z","2026-06-16T05:54:07.918391Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT02508038","Alpha\u002FBeta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",[26],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.192915Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT04851119","Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors",[45],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:29.139986Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":71,"content_modified":201},"NCT07087002","GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults",[26],"2026-05-05T02:43:28.714199Z",{"nct_id":203,"title":204,"phases":205,"status":13,"updated_at":206,"content_modified":207},"NCT05135975","A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",[12],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.530799Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT04308330","Vorinostat in Combination With Chemotherapy in Relapsed\u002FRefractory Solid Tumors and CNS Malignancies",[26],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.511395Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[26],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06500819","Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed\u002FRefractory Solid Tumors",[26],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.289390Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT06395103","Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A\u002FLIGHTBEAM-U01)",[45],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.012234Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT05238792","Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors",[26],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.959678Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT01804634","Reduced Intensity Haploidentical BMT for High Risk Solid Tumors",[12],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:27.448232Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT05642455","SPEARHEAD-3 Pediatric Study",[45],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.852369Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":106,"content_modified":254},"NCT04901702","Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",[45],"2026-05-05T02:35:31.688370Z",{"nct_id":256,"title":257,"phases":258,"status":13,"updated_at":259,"content_modified":260},"NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56",[45],"2026-08-26T02:18:04.640417Z","2026-07-05T05:32:16.773657Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":212,"content_modified":265},"NCT04084067","Indocyanine Green (ICG) Guided Tumor Resection",[26],"2026-05-05T02:43:28.715739Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT07635056","Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma",[12],"2026-08-26T02:17:47.813245Z","2026-06-14T18:39:22.253030Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":276,"content_modified":277},"NCT01587300","Neuroblastoma Biology Study",[],"2026-08-26T02:19:12.219640Z","2026-05-13T02:55:06.075028Z",{"nct_id":279,"title":280,"phases":281,"status":13,"updated_at":282,"content_modified":283},"NCT00588068","Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome",[],"2026-08-26T02:16:06.684983Z","2026-05-13T02:55:06.038766Z",{"nct_id":285,"title":286,"phases":287,"status":13,"updated_at":288,"content_modified":289},"NCT06674811","Biomarkers of Resiliency In Childhood Cancer Surgery",[],"2026-08-26T02:19:22.562392Z","2026-05-13T02:55:06.561222Z",{"nct_id":291,"title":292,"phases":293,"status":13,"updated_at":294,"content_modified":295},"NCT03568669","Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.172955Z",{"nct_id":297,"title":298,"phases":299,"status":13,"updated_at":27,"content_modified":300},"NCT07630974","A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D\u002FLIGHTBEAM-U01)",[45],"2026-07-19T19:36:05.145854Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT07698899","A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)",[26],"2026-08-26T02:18:49.989941Z","2026-07-19T19:36:05.081790Z",[308,312,316],{"biomarker":309,"count":310,"slug":311},"MYCN Gene",8,"mycn-gene",{"biomarker":313,"count":314,"slug":315},"CD276 wt Allele",3,"cd276-wt-allele",{"biomarker":317,"count":314,"slug":318},"Ganglioside GD2","ganglioside-gd2",[320,324,328,331,335,339,343,347,351,354,358,361,364,368,372,376,379,382,385,389,392,395,398,401],{"state":321,"count":322,"slug":323},"Pennsylvania",25,"pennsylvania",{"state":325,"count":326,"slug":327},"California",23,"california",{"state":329,"count":326,"slug":330},"New York","new-york",{"state":332,"count":333,"slug":334},"Texas",22,"texas",{"state":336,"count":337,"slug":338},"Tennessee",20,"tennessee",{"state":340,"count":341,"slug":342},"Massachusetts",19,"massachusetts",{"state":344,"count":345,"slug":346},"Georgia",16,"georgia",{"state":348,"count":349,"slug":350},"Missouri",15,"missouri",{"state":352,"count":349,"slug":353},"Ohio","ohio",{"state":355,"count":356,"slug":357},"Florida",14,"florida",{"state":359,"count":356,"slug":360},"Minnesota","minnesota",{"state":362,"count":356,"slug":363},"North Carolina","north-carolina",{"state":365,"count":366,"slug":367},"Colorado",13,"colorado",{"state":369,"count":370,"slug":371},"Michigan",12,"michigan",{"state":373,"count":374,"slug":375},"Alabama",11,"alabama",{"state":377,"count":374,"slug":378},"Connecticut","connecticut",{"state":380,"count":374,"slug":381},"District of Columbia","district-of-columbia",{"state":383,"count":374,"slug":384},"New Jersey","new-jersey",{"state":386,"count":387,"slug":388},"Illinois",10,"illinois",{"state":390,"count":387,"slug":391},"Washington","washington",{"state":393,"count":310,"slug":394},"Arkansas","arkansas",{"state":396,"count":310,"slug":397},"Hawaii","hawaii",{"state":399,"count":310,"slug":400},"Maryland","maryland",{"state":402,"count":310,"slug":403},"Oregon","oregon"]